An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Name: An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Creator: Vivli
Published: 2024-12-02 16:23:19
License: 暂无描述

DataCite Commons2024-12-02 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/00002512/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD) and disease response of IXAZOMIB administered orally in patients with relapsed and/or refractory multiple myeloma.

提供机构：

Vivli

创建时间：

2018-10-27